Literature DB >> 26461167

Comparison of effects produced by nicotine and the α4β2-selective agonist 5-I-A-85380 on intracranial self-stimulation in rats.

Kelen Freitas1, F Ivy Carroll2, S Stevens Negus1.   

Abstract

Intracranial self-stimulation (ICSS) is one type of preclinical procedure for research on pharmacological mechanisms that mediate abuse potential of drugs acting at various targets, including nicotinic acetylcholine receptors (nAChRs). This study compared effects of the nonselective nAChR agonist nicotine (0.032-1.0 mg/kg) and the α4β2-selective nAChR agonist 5-I-A-85380 (0.01-1.0 mg/kg) on ICSS in male Sprague-Dawley rats. Rats were implanted with electrodes targeting the medial forebrain bundle at the level of the lateral hypothalamus and trained to respond under a fixed-ratio 1 schedule for a range of brain stimulation frequencies (158-56 Hz). A broad range of 5-I-A-85380 doses produced an abuse-related increase (or "facilitation") of low ICSS rates maintained by low brain-stimulation frequencies, and this effect was blocked by both the nonselective nAChR antagonist mecamylamine and the selective α4β2 antagonist dihyrdo-β-erythroidine (DHβE). Conversely, nicotine produced weaker ICSS facilitation across a narrower range of doses, and higher nicotine doses decreased high rates of ICSS maintained by high brain-stimulation frequencies. The rate-decreasing effects of a high nicotine dose were blocked by mecamylamine but not DHβE. Chronic nicotine treatment produced selective tolerance to rate-decreasing effects of nicotine but did not alter ICSS rate-increasing effects of nicotine. These results suggest that α4β2 receptors are sufficient to mediate abuse-related rate-increasing effects of nAChR agonists in this ICSS procedure. Conversely, nicotine effects at non-α4β2 nAChRs appear to oppose and limit abuse-related effects mediated by α4β2 receptors, although tolerance can develop to these non-α4β2 effects. Selective α4β2 agonists may have higher abuse potential than nicotine. PsycINFO Database Record (c) 2016 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26461167      PMCID: PMC4821675          DOI: 10.1037/pha0000055

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  53 in total

1.  Acute and chronic tolerance to nicotine measured by activity in rats.

Authors:  I P Stolerman; R Fink; M E Jarvik
Journal:  Psychopharmacologia       Date:  1973-06-29

2.  Effectiveness of nicotinic agonists as desensitizers at presynaptic α4β2- and α4α5β2-nicotinic acetylcholine receptors.

Authors:  Charles R Wageman; Michael J Marks; Sharon R Grady
Journal:  Nicotine Tob Res       Date:  2013-09-19       Impact factor: 4.244

Review 3.  Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.

Authors:  Christie D Fowler; Paul J Kenny
Journal:  Neuropharmacology       Date:  2013-09-18       Impact factor: 5.250

4.  Self-administration in rats allowed unlimited access to nicotine.

Authors:  J D Valentine; J S Hokanson; S G Matta; B M Sharp
Journal:  Psychopharmacology (Berl)       Date:  1997-10       Impact factor: 4.530

5.  Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats.

Authors:  C T Bauer; M L Banks; B E Blough; S S Negus
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Effects of the specific α4β2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine reward-related behaviors in rats and mice.

Authors:  K M Tobey; D M Walentiny; J L Wiley; F I Carroll; M I Damaj; M R Azar; G F Koob; O George; L S Harris; R E Vann
Journal:  Psychopharmacology (Berl)       Date:  2012-04-22       Impact factor: 4.530

7.  Nicotine maintains robust self-administration in rats on a limited-access schedule.

Authors:  W A Corrigall; K M Coen
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors.

Authors:  A G Mukhin; D Gündisch; A G Horti; A O Koren; G Tamagnan; A S Kimes; J Chambers; D B Vaupel; S L King; M R Picciotto; R B Innis; E D London
Journal:  Mol Pharmacol       Date:  2000-03       Impact factor: 4.436

9.  Effect of chronic nicotine on brain stimulation reward. II. An escalating dose regimen.

Authors:  M A Bozarth; C M Pudiak; R KuoLee
Journal:  Behav Brain Res       Date:  1998-11       Impact factor: 3.332

10.  Acute and chronic nicotine effects on multiple-schedule behavior: oral and SC routes.

Authors:  C E Lau; D J Spear; J L Falk
Journal:  Pharmacol Biochem Behav       Date:  1994-05       Impact factor: 3.533

View more
  9 in total

Review 1.  Determinants of opioid abuse potential: Insights using intracranial self-stimulation.

Authors:  S Stevens Negus; Megan J Moerke
Journal:  Peptides       Date:  2018-11-01       Impact factor: 3.750

2.  Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats.

Authors:  Farhana Sakloth; Elizabeth Leggett; Megan J Moerke; E Andrew Townsend; Matthew L Banks; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2019-01-10       Impact factor: 3.157

3.  Effects of repeated treatment with methcathinone, mephedrone, and fenfluramine on intracranial self-stimulation in rats.

Authors:  J A Suyama; M L Banks; S S Negus
Journal:  Psychopharmacology (Berl)       Date:  2018-09-19       Impact factor: 4.530

4.  Opposing effects of dopamine D1- and D2-like agonists on intracranial self-stimulation in male rats.

Authors:  Matthew F Lazenka; Luke P Legakis; S Stevens Negus
Journal:  Exp Clin Psychopharmacol       Date:  2016-03-17       Impact factor: 3.157

5.  Effects of nicotinic acetylcholine receptor agonists in assays of acute pain-stimulated and pain-depressed behaviors in rats.

Authors:  Kelen C Freitas; F Ivy Carroll; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2015-11       Impact factor: 4.030

6.  Relief of Pain-Depressed Behavior in Rats by Activation of D1-Like Dopamine Receptors.

Authors:  Matthew F Lazenka; Kelen C Freitas; Sydney Henck; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2017-04-14       Impact factor: 4.030

Review 7.  More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.

Authors:  M J Moerke; L R McMahon; J L Wilkerson
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

8.  Effects of nicotine-containing and "nicotine-free" e-cigarette refill liquids on intracranial self-stimulation in rats.

Authors:  Andrew C Harris; Peter Muelken; John R Smethells; Katrina Yershova; Irina Stepanov; Thao Tran Olson; Kenneth J Kellar; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2018-02-01       Impact factor: 4.492

9.  Propylene glycol, a major electronic cigarette constituent, attenuates the adverse effects of high-dose nicotine as measured by intracranial self-stimulation in rats.

Authors:  Andrew C Harris; Peter Muelken; Zach Haave; Yayi Swain; John R Smethells; Mark G LeSage
Journal:  Drug Alcohol Depend       Date:  2018-10-18       Impact factor: 4.492

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.